BEAM THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.26 USD | -5.68% |
|
-8.08% | -21.90% |
| May. 07 | Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates | MT |
| May. 07 | Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechHuidong Wang (Analysts)Good afternoon. My name is Gena Wang. I'm SMid-Cap Biot...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
21.26
USD
Average target price
48.38
USD
Spread / Average Target
+127.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.90% | 1.68B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- BEAM Stock
- News Beam Therapeutics Inc.
- Transcript : Beam Therapeutics Inc. Presents at Barclays Global Healthcare Conference 2021, Mar-11-2021 02
